Rectal Cancer
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)
- Details
ClinicalTrials.gov ID:
NCT06750094
Diagnosis Type:
NA
USOR Number:
- Address
,
P: